Results of the COMPARE trial of Constraint-induced or Multimodality Aphasia Therapy compared with usual care in chronic post-stroke aphasia. Issue 6 (8th April 2022)
- Record Type:
- Journal Article
- Title:
- Results of the COMPARE trial of Constraint-induced or Multimodality Aphasia Therapy compared with usual care in chronic post-stroke aphasia. Issue 6 (8th April 2022)
- Main Title:
- Results of the COMPARE trial of Constraint-induced or Multimodality Aphasia Therapy compared with usual care in chronic post-stroke aphasia
- Authors:
- Rose, Miranda L
Nickels, Lyndsey
Copland, David
Togher, Leanne
Godecke, Erin
Meinzer, Marcus
Rai, Tapan
Cadilhac, Dominique A
Kim, Joosup
Hurley, Melanie
Foster, Abby
Carragher, Marcella
Wilcox, Cassie
Pierce, John E
Steel, Gillian - Abstract:
- Abstract : Background: While meta-analyses confirm treatment for chronic post-stroke aphasia is effective, a lack of comparative evidence for different interventions limits prescription accuracy. We investigated whether Constraint-Induced Aphasia Therapy Plus (CIAT-plus) and/or Multimodality Aphasia Therapy (M-MAT) provided greater therapeutic benefit compared with usual community care and were differentially effective according to baseline aphasia severity. Methods: We conducted a three-arm, multicentre, parallel group, open-label, blinded endpoint, phase III, randomised-controlled trial. We stratified eligible participants by baseline aphasia on the Western Aphasia Battery-Revised Aphasia Quotient (WAB-R-AQ). Groups of three participants were randomly assigned (1:1:1) to 30 hours of CIAT-Plus or M-MAT or to usual care (UC). Primary outcome was change in aphasia severity (WAB-R-AQ) from baseline to therapy completion analysed in the intention-to-treat population. Secondary outcomes included word retrieval, connected speech, functional communication, multimodal communication, quality of life and costs. Results: We analysed 201 participants (70 in CIAT-Plus, 70 in M-MAT and 61 in UC). Aphasia severity was not significantly different between groups at postintervention: 1.05 points (95% CI −0.78 to 2.88; p=0.36) UC group vs CIAT-Plus; 1.06 points (95% CI −0.78 to 2.89; p=0.36) UC group vs M-MAT; 0.004 points (95% CI −1.76 to 1.77; p=1.00) CIAT-Plus vs M-MAT. Word retrieval,Abstract : Background: While meta-analyses confirm treatment for chronic post-stroke aphasia is effective, a lack of comparative evidence for different interventions limits prescription accuracy. We investigated whether Constraint-Induced Aphasia Therapy Plus (CIAT-plus) and/or Multimodality Aphasia Therapy (M-MAT) provided greater therapeutic benefit compared with usual community care and were differentially effective according to baseline aphasia severity. Methods: We conducted a three-arm, multicentre, parallel group, open-label, blinded endpoint, phase III, randomised-controlled trial. We stratified eligible participants by baseline aphasia on the Western Aphasia Battery-Revised Aphasia Quotient (WAB-R-AQ). Groups of three participants were randomly assigned (1:1:1) to 30 hours of CIAT-Plus or M-MAT or to usual care (UC). Primary outcome was change in aphasia severity (WAB-R-AQ) from baseline to therapy completion analysed in the intention-to-treat population. Secondary outcomes included word retrieval, connected speech, functional communication, multimodal communication, quality of life and costs. Results: We analysed 201 participants (70 in CIAT-Plus, 70 in M-MAT and 61 in UC). Aphasia severity was not significantly different between groups at postintervention: 1.05 points (95% CI −0.78 to 2.88; p=0.36) UC group vs CIAT-Plus; 1.06 points (95% CI −0.78 to 2.89; p=0.36) UC group vs M-MAT; 0.004 points (95% CI −1.76 to 1.77; p=1.00) CIAT-Plus vs M-MAT. Word retrieval, functional communication and communication-related quality of life were significantly improved following CIAT-Plus and M-MAT. Word retrieval benefits were maintained at 12-week follow-up. Conclusions: CIAT-Plus and M-MAT were effective for word retrieval, functional communication, and quality of life, while UC was not. Future studies should explore predictive characteristics of responders and impacts of maintenance doses. Trial registration number: ACTRN 2615000618550. … (more)
- Is Part Of:
- Journal of neurology, neurosurgery and psychiatry. Volume 93:Issue 6(2022)
- Journal:
- Journal of neurology, neurosurgery and psychiatry
- Issue:
- Volume 93:Issue 6(2022)
- Issue Display:
- Volume 93, Issue 6 (2022)
- Year:
- 2022
- Volume:
- 93
- Issue:
- 6
- Issue Sort Value:
- 2022-0093-0006-0000
- Page Start:
- 573
- Page End:
- 581
- Publication Date:
- 2022-04-08
- Subjects:
- aphasia -- rehabilitation -- randomised trials -- stroke
Neurology -- Periodicals
Nervous system -- Surgery -- Periodicals
Psychiatry -- Periodicals
616.8 - Journal URLs:
- http://jnnp.bmjjournals.com/ ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?action=archive&journal=192 ↗
http://www.bmj.com/archive ↗ - DOI:
- 10.1136/jnnp-2021-328422 ↗
- Languages:
- English
- ISSNs:
- 0022-3050
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22238.xml